PBAC Public Summary Documents – March 2023
Page last updated: 22 December 2023
Public Summary Documents relating to the March 2023 PBAC meeting.
- Abemaciclib: Tablet 50 mg, Tablet 100 mg, Tablet 150 mg; Verzenio®
- Acalabrutinib: Capsule 100 mg; Calquence®
- Alirocumab: Injection 300 mg in 2 mL single dose autoinjector; Praluent®
- Amino acid formula with vitamins and minerals, without methionine and supplemented with arachidonic acid and docosahexaenoic acid: Sachets containing oral powder 12.5 g, 30 (HCU explore5); HCU explore5™
- Amino acid formula with vitamins and minerals, without phenylalanine and tyrosine and supplemented with arachidonic acid and docosahexaenoic acid: Sachets containing oral powder 12.5 g, 30 (TYR explore5); TYR explore5™
- Amino acid formula with vitamins and minerals without valine, leucine and isoleucine and supplemented with arachidonic acid and docosahexaenoic acid: Sachets containing oral powder 12.5 g, 30 (MSUD explore5); MSUD explore5™
- Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids: Oral powder 400 g (EleCare LCP); EleCare® LCP
- Anifrolumab: Solution concentrate for I.V. infusion 300 mg in 2 mL vial; Saphnelo®
- Apremilast: Tablet 30 mg, Pack containing 4 tablets of 10 mg, 4 tablets of 20 mg, 19 tablets of 30 mg; Otezla®
- Bimekizumab: Injection 160 mg in 1 mL single use pre-filled syringe, Injection 160 mg in 1 mL single use pre-filled pen; Bimzelx®
- Budesonide: Tablet 500 micrograms (orally disintegrating), Tablet 1 mg (orally disintegrating); Jorveza® - July 2023
- Carmellose with glycerin and with hyaluronic acid: Eye drops containing carmellose sodium 5 mg with glycerin 9 mg and with hyaluronic acid 1 mg per mL, 10 mL; Optive Fusion® - May 2023
- Chlormethine hydrochloride: 0.016% (160 microgram/g) gel; Ledaga®
- Daratumumab: Solution for I.V. infusion 100 mg in 5 mL vial, Solution for I.V. infusion 400 mg in 20 mL vial, Solution for S.C. injection 1,800 mg in 15 mL vial; Darzalex®
- Difelikefalin: Solution for I.V. injection 50 mcg in 1 mL vial; Korsuva®
- Durvalumab: Solution concentrate for I.V. infusion 120 mg in 2.4 mL vial, Solution concentrate for I.V. infusion 500 mg in 10 mL vial; Imfinzi®
- Enzalutamide: Capsule 40 mg; Xtandi®
- Finerenone: Tablet 10 mg, Tablet 20 mg; Kerendia®
- Fosnetupitant (as chloride hydrochloride)/palonosetron (as hydrochloride): Solution concentrate for I.V. infusion containing fosnetupitant 235 mg and palonosetron 0.25 mg in 20 mL vial; Akynzeo®IV
- Glycomacropeptide and essential amino acids with vitamins and minerals: Oral liquid 250 mL, 30 (Tylactin RTD); Tylactin RTD
- Glycomacropeptide and essential amino acids with vitamins and minerals: Sachets containing oral powder 40 g, 30 (Camino Pro Bettermilk); Camino Pro Bettermilk. Oral liquid 250 mL, 30 (PKU Glytactin RTD 15); PKU Glytactin RTD 15
- High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate: Oral liquid 250 mL, 30; KetoVie 3:1. Oral liquid 250 mL, 30; KetoVie 4:1. Oral liquid 250 mL, 30; KetoVie Peptide 4:1
- Hyaluronic acid with polyethylene glycol 400 with propylene glycol with hydroxypropyl guar: Eye drops containing sodium hyaluronate 1.5 mg per mL with polyethylene glycol 400, propylene glycol and hydroxypropyl guar, 10 mL; Systane® Hydration - May 2023
- Inclisiran: Injection 284 mg in 1.5 mL single use pre-filled syringe; Leqvio® - May 2023
- Mifepristone and misoprostol: Pack containing 1 tablet mifepristone 200 mg and 4 tablets misoprostol 200 micrograms; MS-2 Step®
- Natalizumab: Injection 150 mg in 1 mL single dose pre-filled syringe; Tysabri®
- Netupitant with palonosetron: Capsule containing netupitant 300 mg with palonosetron 500 microgram (as hydrochloride); Akynzeo®
- Niraparib: Capsule 100 mg; Zejula® - July 2023
- Nivolumab (gastro-oesophageal cancers): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®
- Nivolumab (NSCLC): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®
- Olaparib: Tablet 100 mg, Tablet 150 mg; Lynparza®
- Osilodrostat: Tablet 1 mg, Tablet 5 mg, Tablet 10 mg; Isturisa®
- Patiromer: Sachet, 8.4 g powder for oral liquid, Sachet, 16.8 g powder for oral liquid; Veltassa®
- Pembrolizumab (metastatic breast cancer): Solution concentrate for I.V. infusion 100 mg in 4 mL vial; Keytruda®
- Pembrolizumab (early breast cancer): Solution concentrate for I.V. infusion 100 mg in 4 mL vial; Keytruda®
- Pemetrexed: Solution concentrate for I.V. infusion 100 mg in 4 mL vial, Solution concentrate for I.V. infusion 500 mg in 20 mL vial, Solution concentrate for I.V. infusion 1000 mg in 40 mL vial; Pemetrexed EVER Pharma
- Pneumococcal conjugate vaccine, 15 valent adsorbed: 0.5 mL pre-filled syringe; Vaxneuvance®
- Ravulizumab: Solution concentrate for I.V. infusion 300 mg in 3 mL vial, Solution concentrate for I.V. infusion 1.1 g in 11 mL vial; Ultomiris® - July 2023
- Relatlimab and nivolumab: Solution concentrate for I.V. infusion containing 80 mg relatlimab and 240 mg nivolumab in 20 mL vial; Opdualag®- July 2023
- Risdiplam: Powder for oral solution 0.75 mg per 1 mL, 80 mL; Evrysdi®
- Romosozumab: Injection 105 mg in 1.17 mL single use pre-filled syringe; Evenity®
- Tebentafusp: Solution concentrate for I.V. infusion 100 mcg in 0.5 mL vial; Kimmtrak® - September 2023
- Ticagrelor: Tablet, 90 mg; Brilinta®
- Tildrakizumab: Injection 100 mg in 1 mL single dose pre-filled syringe; Ilumya®
- Tofacitinib (ankylosing spondylitis): Tablet 5 mg; Xeljanz®
- Tofacitinib (JIA): Tablet 5 mg, Oral liquid 1 mg per mL, 240 mL; Xeljanz®
- Ursodeoxycholic acid: Capsule 250 mg, Tablet 500 mg; Ursofalk®
- Varicella zoster virus recombinant vaccine: Injection [1 vial] & adjuvant substance diluent [0.5 mL vial]; Shingrix®
- Zanubrutinib (naive CLL/SLL): Capsule 80 mg; Brukinsa®
- Zanubrutinib (relapsed/refractory CLL/SLL): Capsule 80 mg; Brukinsa®
The following Public Summary Documents have been updated:
March 2022 PBAC meeting
July 2022 PBAC meeting
November 2022 PBAC meeting
- Deucravacitinib: Tablet 6 mg; Sotyktu®
- Dostarlimab: Solution concentrate for I.V. infusion 500 mg in 10 mL; Jemperli®
- Elexacaftor with tezacaftor and with ivacaftor, and ivacaftor: Pack containing 56 tablets elexacaftor 100 mg with tezacaftor 50 mg and with ivacaftor 75 mg and 28 tablets ivacaftor 150 mg, Pack containing 56 tablets elexacaftor 50 mg with tezacaftor 25 mg and with ivacaftor 37.5 mg and 28 tablets ivacaftor 75 mg; Trikafta®
- Enfortumab Vedotin: Powder for I.V. infusion 20 mg, Powder for I.V. infusion 30 mg; Padcev®
- Risedronic acid: Tablet (enteric coated) containing risedronate sodium 35 mg; Actonel® EC
- Upadacitinib (nr-axSpA): Tablet 15 mg; Rinvoq®
